Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Dermatologic 2Breast 2Head & Neck 1

Conditions

Neoplasms 14Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Stomach Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 2Mesothelioma 2Melanoma 2Head and Neck Neoplasms 2Cholangiocarcinoma 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

pembrolizumab 7fludarabine 4Nivolumab 4Cyclophosphamide 4Radiation 3Interleukin-2 3talimogene laherparepvec 2poly ICLC 2budigalimab 2aldesleukin 2Radiotherapy 2Ipilimumab 2Everolimus 2CTLA-4 Antigen 2zimberelimab 1venetoclax 1veliparib 1vatalanib 1tocilizumab 1temsirolimus 1rovalpituzumab tesirine 1prednylidene 1pentetreotide 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1flt3 ligand protein 1deltacortene 1cixutumumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Merkel Cell × budigalimab × Clear all
NCT03071757 2022-04-28

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

AbbVie

Phase 1 Completed
139 enrolled
BreastDermatologicGastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03000257 2022-04-14

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Completed
182 enrolled
BreastDermatologicGastrointestinalGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡